New hope for long COVID heart sufferers: drug combo trial launches
NCT ID NCT05619653
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of anti-inflammatory and heart-protecting drugs can reduce symptoms and heart damage in people with Long COVID who have ongoing heart inflammation. About 279 adults with heart inflammation seen on MRI will receive either the drug combo or a placebo for several months. The goal is to see if this treatment can improve heart function and reduce symptoms like chest pain and shortness of breath.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 ASSOCIATED CARDIAC INVOLVEMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute for experimental and translational cardiovascular imaging
Frankfurt am Main, Hesse, 60596, Germany
-
University Hospital Greifswald
Greifswald, 17475, Germany
-
University Hospital Schleswig-Holstein, Campus KIEL
Kiel, 24105, Germany
-
University Hospital Ulm
Ulm, 89081, Germany
-
University Medical Centre Vienna
Vienna, 1090, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Could High-Intensity workouts and diet tame chest pain from tiny heart vessels?
- Could exercise retrain the heart in long COVID?
- Can an Hourglass-Shaped device relieve chest pain when arteries Aren't blocked?
- Can brain games and gentle currents lift long COVID brain fog?
- Could a pill shield the brain and kidneys during heart surgery?